UnitedHealthcare to cover OMNI glaucoma procedure starting October

MENLO PARK - UnitedHealthcare (UHC) will update its Glaucoma Surgical Treatments policy to cover several minimally invasive glaucoma procedures, including Sight Sciences’ (NASDAQ:SGHT) OMNI Surgical System, effective October 1, 2025. Sight Sciences, with a market capitalization of $193 million and an impressive gross profit margin of 85%, has maintained a strong financial position with more cash than debt on its balance sheet, according to InvestingPro data.

The updated policy will cover goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma and cataract who are currently using ocular hypotensive medication, when deemed medically necessary.

This coverage applies to UHC’s commercial and individual exchange benefit plans, which represent approximately 30 million of UHC’s more than 50 million total covered lives.

"As a result of this positive coverage policy, UHC’s members will have access to the OMNI technology when deemed medically necessary by their ophthalmologist," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. The company’s stock, currently trading at $3.69, has shown significant momentum with a 56% gain over the past six months, though it remains well below its 52-week high of $7.03. InvestingPro analysis suggests the stock is currently undervalued, with three analysts recently revising their earnings expectations upward.

The OMNI Surgical System is FDA-cleared for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The procedure can be performed before, during, or after cataract surgery.

Sight Sciences describes its OMNI system as an implant-free, minimally invasive glaucoma surgery technology. Glaucoma is the leading cause of irreversible blindness worldwide. For deeper insights into Sight Sciences’ financial health, growth prospects, and detailed analysis, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

The announcement was made in a company press release issued Tuesday.

In other recent news, Sight Sciences Inc. reported its second-quarter 2025 financial results, surpassing expectations with $19.6 million in revenue against a forecast of $18.18 million. The company also reported a narrower-than-expected loss per share of $0.23, compared to the anticipated loss of $0.26. Following these results, Sight Sciences raised its 2025 revenue guidance, indicating a positive outlook for the rest of the year. Lake Street Capital Markets responded to these developments by upgrading Sight Sciences from Hold to Buy, setting a price target of $5.00. This upgrade highlights the firm’s confidence in the company’s stabilizing business. Despite the positive earnings report, Sight Sciences’ stock experienced a decline in after-hours trading, which may reflect investor caution amidst broader market trends. These recent developments underscore the dynamic environment in which Sight Sciences operates.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.